NVUS News and Press, Novus Therapeutics Inc. From 01/10/20

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the agreement by several accredited investors to exercise certain warrants to purchase up to an aggregate ...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate in two investor conferences in December. Piper Jaffray 31st Annual ...

Novus Therapeutics (NASDAQ: NVUS ): Q3 GAAP EPS of -$0.22 beats by $0.19 . More news on: Novus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-- Management to participate in two investor conferences in December 2019 -- -- Data from ongoing phase 2a study C-006 expected in the first half of 2020 -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients ...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the U.S. Food and Drug Administration (FDA) has agreed with the Company’s proposed patient pop...

The following slide deck was published by Novus Therapeutics, Inc. in conjunction with this Read more ...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate in two upcoming investor conferences in New York City. H.C. Wainwri...

Novus Therapeutics (NASDAQ: NVUS ): Q2 GAAP EPS of -$0.35 beats by $0.07 . More news on: Novus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended June 30, 2019. Operational Highlights Announced result...

SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced th...